Name
RF6-06: (PROs) in DESTINY-Breast11: (NAT) with (T-DXd) alone or followed by (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC) - Commentary By: Giuseppe Curigliano, MD, PhD
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL